NCT04666038 2026-04-24BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled